

Claims 1 and 2 have also been amended to recite "polyclonal antibody." Support can be found, for example, at page 5, line 12.

The specification has been amended to direct the entry of this sequence listing between the specification and claims of the above-identified application and to provide a SEQ ID NO next to the specific sequence.

These changes are believed to introduce no new matter, and their entry is respectfully requested.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Judith U. Kim
Attorney for Applicants
Registration No. 40,679

Date: October 25, 1999

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600